Hemophilia is a chronic disease and a blood congenital organic disability that mainly affects male individuals.
People with such a condition are affected by bleedings, often spontaneous and particularly around bone joints, which at medium and long term causes joint deformities that have a major impact on these patients' quality of life.
Available treatment for hemophilia consists of replacement of clotting factor, either plasma-derived or recombinant technology products .
Both children and adults with the severe form of the disease (< 1%) go through this prophylactic treatment several times a week, thus trying to prevent bleeding and encouraging for a sustained healthy growth.
Read the whole article here (portuguese only).